Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) Shares Outstanding (Weighted Average) (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Shares Outstanding (Weighted Average) for 15 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) rose 13.82% year-over-year to $1.8 million, compared with a TTM value of $1.8 million through Sep 2025, up 13.82%, and an annual FY2024 reading of $1.6 million, changed 0.11% over the prior year.
  • Shares Outstanding (Weighted Average) was $1.8 million for Q3 2025 at Alaunos Therapeutics, up from $1.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $215.1 million in Q3 2022 and bottomed at $1.6 million in Q2 2023.
  • Average Shares Outstanding (Weighted Average) over 5 years is $81.5 million, with a median of $1.8 million recorded in 2025.
  • The sharpest move saw Shares Outstanding (Weighted Average) crashed 99.26% in 2023, then increased 13.82% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $214.4 million in 2021, then crashed by 93.25% to $14.5 million in 2022, then crashed by 88.95% to $1.6 million in 2023, then increased by 0.11% to $1.6 million in 2024, then grew by 13.82% to $1.8 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for TCRT at $1.8 million in Q3 2025, $1.7 million in Q2 2025, and $1.6 million in Q1 2025.